Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?-Reference-Cited by-同舟云学术

Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?

Published:2019-01 Issue: Volume:198 Page:102-105
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Mastellos Dimitrios C.,Reis Edimara S.,Biglarnia Ali-Reza,Waldman Meryl,Quigg Richard J.,Huber-Lang Markus,Seelen Marc A.,Daha Mohamed R.,Lambris John D.^ORCID

Funder

U.S. National Institutes of Health

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference27 articles.

1. Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes;Chenoweth;Kidney Int.,1983

2. Activation of the alternative pathway of complement by cellulosic hemodialysis membranes;Cheung;Kidney Int.,1989

3. Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis;Deangelis;Immunobiology,2012

4. Cardiovascular disease in haemodialysis: role of the intravascular innate immune system;Ekdahl;Nat. Rev. Nephrol.,2017

5. Thromboinflammation in Therapeutic Medicine;Ekdahl;Adv. Exp. Med. Biol.,2015

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immobilization of novel synthesized phosphobetaine zwitterions on polyethersulphone (PES) hemodialysis membranes to induce hemocompatibility: Experimental, molecular docking, and ex-vivo inflammatory biomarker investigations;Biomedical Engineering Advances;2024-06

2. Hematological and Renal Involvement in Thrombotic Microangiopathies;Comprehensive Hematology and Stem Cell Research;2024

3. Unleashing the power of complement activation: unraveling renal damage in human anti-glomerular basement membrane disease;Frontiers in Immunology;2023-09-15

4. The effect of pomegranate consumption on cardiovascular risk factors in hemodialysis patients: A systematic review of clinical trials;Phytotherapy Research;2023-07-24

5. From discovery to approval: A brief history of the compstatin family of complement C3 inhibitors;Clinical Immunology;2022-02